Optimization of Periodontal Disease Treatment Tactics in Patients With Chronic Hepatitis C After Achieving a Sustained Virological Response
DOI:
https://doi.org/10.5281/zenodo.19970942Ключевые слова:
chronic hepatitis C (CHC), direct-acting antivirals (DAAs), sustained virological response (SVR), hepatitis C virus (HCV), periodontal diseases, dental rehabilitation.Аннотация
The article examines the problem of dental rehabilitation in patients who have achieved recovery from chronic
hepatitis C (CHC) following treatment with direct-acting antivirals (DAAs). Despite viral elimination and the achievement
of a sustained virological response (SVR), pathological changes in periodontal tissues may persist. A research design
is proposed to develop a comprehensive treatment algorithm that considers local immune status and functional hepatic
reserve.
Библиографические ссылки
1. World Health Organization. Global report on health data systems and capacity for viral hepatitis: goals for 2030.
Geneva: WHO; 2024.
2. Nagao Y., Kawahara K., Kawahara M. Impact of systemic inflammation on oral health in patients with chronic hepatitis
C after viral eradication by direct-acting antivirals. J Clin Med. 2022;11(14):4052.
3. Gigliotti J., Perillo L., Castiglia G., et al. Periodontal health and hepatitis C virus: a systematic review and meta-analysis
of the post-DAA era. J Periodontol. 2024;95(3):215-228.
4. Carrozzo M., Francia S. Oral manifestations of hepatitis C virus infection: an update. Oral Dis. 2023;29(Suppl 1):12-25.
5. Makhmudova U.B., Samatov A.A. Specifics of dental status in patients with chronic viral hepatitis C in the Samarkand
region. Journal of Hepato-Gastroenterology Research. 2025;6(2):45-51.
6. Shoukat S., Ahmed R., Khan M. Pro-inflammatory cytokine profiles in oral fluid as predictors of periodontal destruction
in post-HCV patients. Int J Dent Res. 2024;12(1):88-94.
7. Sutton A.J., Edmunds W.J., Gill O.N. Long-term outcomes and “immunological scarring” following successful DAA
therapy for hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(5):441-453.
8. Borgia G., Gentile I. Direct-acting antivirals and extrahepatic manifestations: a new paradigm in HCV management.
World J Hepatol. 2024;16(4):112-120.
9. Lalla E., Papapanou P.N. Diabetes, hepatitis, and periodontal disease: the common inflammatory link. Periodontol
2000. 2023;91(1):135-152.
10. Zhamoityn A., Sadykova G. Evaluation of liver fibrosis using FibroScan in patients with periodontal disease: a
cross-sectional study. Central Asian J Med. 2025;9(1):30-38.
11. Gomez R., Martinez M. The role of secretor IgA and lysozyme in the oral defense of patients after viral hepatitis treatment.
Oral Health Prev Dent. 2025;23(2):155-163.
12. Porphyromonas gingivalis and the systemic inflammatory burden: a focus on hepatobiliary patients. J Dent Res.
2024;103(6):541-550.
13. Bedossa P. Liver fibrosis and the METAVIR score: clinical implications for multidisciplinary care. Clin Liver Dis.
2023;27(2):201-215.
14. Ismoilov S.I., et al. Epidemiological features of parenteral hepatitis in Uzbekistan: current trends and challenges.
Uzbek Med J. 2024;5(3):10-18.
15. GraphPad Software. Statistical analysis of clinical data in periodontal research. 10th ed. San Diego; 2024.
Загрузки
Опубликован
Выпуск
Раздел
Лицензия
Copyright (c) 2026 MAKTABGACHA VA MAKTAB TA’LIMI JURNALI
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
